News for Profound Medical Corp. (PROF)

Profound Medical (PROF) recently marked a significant achievement with the successful execution of the first commercial procedure for benign prostatic hyperplas

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF; TSX:PRN) (”œProfound” or the ”œCompany”), a commercial-stage medical device com

Profound Medical, under the ticker PROF, has signed a consulting agreement with Leonard Wheeler, a former NFL player and now an entrepreneur and corporate consu

Leonard Wheeler appointed as Global Ambassador for Profound Medical's TULSA-PRO system after successful personal treatment. The TULSA-PRO system offers

TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF; TSX:PRN) (”œProfound” or the ”œCompany”), a commercial-stage medical device com

**media[626276]**

Shares of Coinbase Global, Inc. COIN rose sharply in today's pre-market trading. Coinbase is set to join the S&P 500, replacing Discover Financial Services DFS...

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.5% on Friday. Shares of Expedia Group, Inc. EXPE fell sharply in today's ...

Profound Medical Corporation (NASDAQ:PROF) Q1 2025 - Earnings Conference Call May 8, 2025 4:30 PM ETCompany ParticipantsStephen Kilmer - Head IRRashed Dewan...

Shares of Pinterest, Inc. PINS rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter sales results and issued...

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Profound Medical

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NPRN.TO - Profound Medical CorpQ1 2025 Profound Medical Corp Earnings CallMay 08, 2025 / 08:30P

Revenue: $2.6 million, missing the estimated $3.10 million, but marking an 82% increase from the same period last year.Gross Margin: Improved to 71% from 60% i

TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF; TSX:PRN) (”œProfound” or the ”œCompany”), a commercial-stage medical device comp

Profound Medical has an innovative product, Tulsa Pro, for prostate cancer and BPH. Click here to read an analysis of PROF stock now.

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. (”œProfound” or the ”

Profound Medical (PROF) shared encouraging early data from its CAPTAIN trial, which compares the safety and effectiveness of the TULSA procedure against radical

”“ First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer ”“ ”“ TULSA had no blood loss and no overnight stay

PR NewswireNEW YORK, April 28, 2025 NEW YORK, April 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medic